TOP TEN perturbations for O43674 (Homo sapiens)

Organism: Homo sapiens
Gene: O43674
Selected probe(set): 203621_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of O43674 (203621_at) across 5610 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.382434
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.053008
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

Alzheimer's disease study 9 / normal pyramidal neuron (posterior cingulate)

Relative Expression (log2-ratio):-2.0227861
Number of Samples:9 / 13
Experimental Alzheimer's disease study 9
Cortical layer III pyramidal neurons of the posterior cingulate of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal pyramidal neuron (posterior cingulate)
Cortical layer III pyramidal neurons of the posterior cingulate of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-1.7585764
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):1.7423277
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):1.74119
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

breast cancer study 4 / normal organelle sample

Relative Expression (log2-ratio):1.7123375
Number of Samples:4 / 12
Experimental breast cancer study 4
Breast BRCA1-deficient tumor samples.
Control normal organelle sample
Normal organelle samples.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-1.7019901
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

SDF study 4 / untreated MDA Mb231 cell sample

Relative Expression (log2-ratio):1.6837444
Number of Samples:3 / 6
Experimental SDF study 4
MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control untreated MDA Mb231 cell sample
Untreated MDA Mb231 cells harvested after 6h.

breast cancer study 3 / normal organelle sample

Relative Expression (log2-ratio):1.6517677
Number of Samples:17 / 12
Experimental breast cancer study 3
Breast basal tumor samples.
Control normal organelle sample
Normal organelle samples.